And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is fairly modest. We hope to hang with Mrs. Pharmalot, catch up on our reading, and promenade with the spirited official mascot. And what about you? This remains a fine time to enjoy the great outdoors or to take a well-deserved nap. You could sign up for a Covid-19 vaccination or reach out to someone feeling isolated. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you on Tuesday, since we have an extended holiday weekend on this side of the pond. …

The U.S. has finalized a previously announced deal with Pfizer (PFE) and Moderna (MRNA) for 200 million more Covid-19 vaccine doses, which President Biden says should be enough to vaccinate every American, NBC News tells us. Biden said the federal government signed the final contracts Thursday afternoon for 100 million more doses of the Moderna vaccine and 100 million more from Pfizer and BioNTech (BNTX). Last month, Biden said he was directing the government to secure more doses on top of the 400 million ordered during the Trump administration.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]